<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58560">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01721434</url>
  </required_header>
  <id_info>
    <org_study_id>Levo2</org_study_id>
    <nct_id>NCT01721434</nct_id>
  </id_info>
  <brief_title>Effects of Levosimendan on Diaphragm Function in Mechanically Ventilated Patients</brief_title>
  <official_title>Effects of Levosimendan on Diaphragm Function in Mechanically Ventilated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Nijmegen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Nijmegen</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Levosimendan is a relatively new drug that improves cardiac contractility in patients with
      heart failure. Its main mechanism of action is enhanced binding of calcium to the myocardial
      contractile proteins. Recent data from our lab showed that levosimendan improves
      contractility of human diaphragm in vitro (muscle fibers from COPD patient diaphragm) and in
      vivo (healthy subjects). Accordingly, levosimendan may appear of value in the treatment of
      disorders associated with impaired respiratory muscle function, such as mechanically
      ventilated patients.We hypothesize that levosimendan could improve respiratory muscle
      function in mechanically ventilated patients commencing a CPAP trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Neuro-mechanical efficiency of the diaphragm</measure>
    <time_frame>Artefact-free periode in the last 10 minutes of each CPAP trial</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome measure is the neuro-mechanical efficiency(i.e. the ratio of diaphragm electrical activity and transdiaphragmatic pressure) of the diaphragm during a continuous positive airway pressure (CPAP) trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuro-ventilatory efficiency of the diaphragm</measure>
    <time_frame>Artefact-free periode in the last 10 minutes of each CPAP trial</time_frame>
    <safety_issue>No</safety_issue>
    <description>A secondary outcome measure is the neuro-ventilatory efficiency (i.e. the ratio of diaphragm electrical activity and tidal volume) during a continuous positive airway pressure (CPAP) trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen consumption (VO2)</measure>
    <time_frame>Artefact-free periode in the last 10 minutes of each CPAP trial</time_frame>
    <safety_issue>No</safety_issue>
    <description>A secondary outcome measure is the oxygen consumption during a continuous positive airway pressure (CPAP) trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial pressure of oxygen in arterial blood (PaO2)</measure>
    <time_frame>Last minute of the 30 minute CPAP trial</time_frame>
    <safety_issue>No</safety_issue>
    <description>A secondary outcome measure is the PaO2 at the end of a continuous positive airway pressure (CPAP) trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accessory respiratory muscle activity</measure>
    <time_frame>Measured during a one hour protocol after the second CPAP trial.</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the effects of levosimendan on accessory respiratory muscle function, ventilator settings are adapted after the last CPAP-trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbon dioxide production (VCO2)</measure>
    <time_frame>Artefact-free periode in the last 10 minutes of each CPAP trial</time_frame>
    <safety_issue>No</safety_issue>
    <description>A secondary outcome measure is the carbon dioxide production during a continuous positive airway pressure (CPAP) trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial pressure of carbon dioxide in arterial blood (PaCO2)</measure>
    <time_frame>Last minute of the 30 minute CPAP trial</time_frame>
    <safety_issue>No</safety_issue>
    <description>A secondary outcome measure is the PaCO2 at the and of a continuous positive airway pressure (CPAP) trial.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Muscle Weakness Conditions</condition>
  <condition>Weaning Failure</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levosimendan 0.2 ug/kg/min intravenous for a single 7 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Similar coloured placebo intravenous for a single 7 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <arm_group_label>Levosimendan</arm_group_label>
    <other_name>Simdax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Similar coloured placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mechanical ventilation &gt; 3 days

          -  informed consent

          -  able to sustain a CPAP trial for 30 minutes

          -  PaO2/FiO2 ratio &gt; 200 mmHg

          -  ventilatory settings: positive end expiratory pressure &lt;= 10 cmH2O,    pressure
             support &lt;= 10 cmH2O

        Exclusion Criteria:

          -  pre-existent muscle disease (congenital or acquired) or diseases/disorders known to
             be associated with myopathy including auto-immune diseases

          -  pre-existent cardiac disease (based on history, electrocardiography and transthoracic
             echocardiography)

          -  upper airway/esophageal pathology (i.e. recent surgery, esophageal varices,
             diaphragmatic hernia)

          -  phrenic nerve lesions

          -  pregnancy, breast feeding

          -  severe renal failure (serum creatinine &gt; 150 umol/L)

          -  severe hepatic failure

          -  recent (within 5 days) nasal bleeding

          -  systolic blood pressure &lt; 120 mmHg
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo Heunks, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leo MA Heunks, MD, PhD</last_name>
    <phone>024-3617273</phone>
    <email>l.heunks@ic.umcn.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonne Doorduin, MSc</last_name>
    <phone>024-3617273</phone>
    <email>j.doorduin@ic.umcn.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo MA Heunks, MD, PhD</last_name>
      <phone>024-3617273</phone>
      <email>l.heunks@ic.umcn.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jonne Doorduin, MSc</last_name>
      <phone>024-3617273</phone>
      <email>j.doorduin@ic.umcn.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 1, 2012</lastchanged_date>
  <firstreceived_date>September 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Nijmegen</investigator_affiliation>
    <investigator_full_name>Leo Heunks</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>levosimendan</keyword>
  <keyword>diaphragm function</keyword>
  <keyword>mechanically ventilated patients</keyword>
  <keyword>neuro-mechanical efficiency</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
